Stay updated with breaking news from Solid Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...
/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...
10/01/21 Life Science Leader Newsletter
Ogilvy and McCann heavyweight Andrew Schirmer has joined Syneos Health's GSW New York as president. Three members of the FDA panel that argued against aducanumab have quit in the wake of the Alzheimer's drug's approval. Inogen, recently equipped with a new CEO, has tapped BD vet Stanislav Glezer, M.D., as its chief medical officer.
Dive Brief: Sarepta Therapeutics on Tuesday disclosed results from a small but important study, showing a commercial-grade version of its gene therapy for Duchenne muscular dystrophy appears comparable to the product it used in earlier clinical testing. The first 11 patients to receive the commercial version of the therapy produced an average of 55.4% of normal levels of "micro" dystrophin — a shortened form of the protein Duchenne patients lack — three months after treatment. That number was 51.7% for a similar group of 11 patients in an earlier trial. No new safety concerns were reporte...